Commission on Human Medicines

Report of the Isotretinoin Implementation Advisory Expert Working Group regarding recommendations to strengthen the safe use of isotretinoin, the acne medicine commonly known by brand names Roaccutane and Reticutan.

MHRA assessment of transient embryonic hypoxia and teratogenicity in relation to oral hormone pregnancy tests (HPTs), as considered by the Commission on Human Medicines (CHM).

Independent report by the Commission on Human Medicines on the safety implications of a proposal to restrict the availability of puberty blockers for under 18s.

Meeting minutes taken from meetings of the Vaccine Benefit Risk Expert Working Group (VBREWG) held between 10 May 2021 to 25 May 2021.

Meeting minutes taken from meetings of the Vaccine Benefit Risk Expert Working Group (VBREWG) held between 13 January 2021 to 15 February 2021.

Meeting minutes taken from meetings of the Vaccine Benefit Risk Expert Working Group (VBREWG) held between 25 February 2021 to 6 April 2021.

Meeting minutes taken from meetings of the Vaccine Benefit Risk Expert Working Group (VBREWG) held between 25 August 2020 to 28 November 2020.

Meeting minutes taken from meetings of the Vaccine Benefit Risk Expert Working Group (VBREWG) held between 12 April 2021 to 4 May 2021.

Meeting minutes taken from meetings of the Vaccine Benefit Risk Expert Working Group (VBREWG) held between 7 December 2020 to 3 January 2021.

Annual Report of the Human Medicines Regulations 2012 Advisory Bodies - the Commission on Human Medicines (CHM) and the British Pharmacopoeia Commission.

Annual Report of the Human Medicines Regulations 2012 Advisory Bodies - the Commission on Human Medicines (CHM) and the British Pharmacopoeia Commission.

We are consulting on a set of proposals to improve and strengthen the Code of Practice for experts who provide advice on which decisions about the regulation of medicines and medical devices are based, to ensure that experts providing the advice are independent and impartial, and that the processes in place to manage conflicts of interest are robust and clear to all.

Annual Report of the Human Medicines Regulations 2012 Advisory Bodies - the Commission on Human Medicines (CHM) and the British Pharmacopoeia Commission

Expert Working Group concludes there is currently insufficient evidence to establish a link between use of ibuprofen and susceptibility to contracting COVID-19 or the worsening of its symptoms.

An Expert Working Group (EWG) of the UK’s Commission on Human Medicines (CHM) has published their report on the benefit-risk and risk minimisation measures of the yellow fever vaccine.

Minutes of the meeting and MHRA assessment report

Minutes of the meeting and MHRA assessment report.

An Expert Working Group (EWG) of the UK’s Commission on Human Medicines (CHM) has published their report on the use of hormone pregnancy tests (HPTs) and adverse effects relating to pregnancy including possible birth defects.